Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | NMT1 | P30419 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18305045 | 0.81 | CDK4 (0.38) | BRD4CHRM1SLC5A2NMT1 | |
| SCHEMBL18305041 | 0.76 | NMT1 (0.36) | CHRM1SLC5A2NMT1 | |
| SCHEMBL20138129 | 0.74 | CHRM1 (0.33) | BRD4CHRM1 | |
| SCHEMBL18305028 | 0.73 | CCNT1 (0.32) | CHRM1 | |
| SCHEMBL20138257 | 0.73 | CD274 (0.38) | BRD4CHRM1SLC5A2 | |
| SCHEMBL20138201 | 0.72 | CDK4 (0.37) | BRD4CHRM1SLC5A2 | |
| SCHEMBL18305005 | 0.70 | CHRM1 (0.32) | CHRM1 | |
| SCHEMBL18305064 | 0.70 | BRD4 (0.38) | BRD4CHRM1SLC5A2NMT1 | |
| SCHEMBL18305039 | 0.70 | IDO1 (0.30) | CHRM1 | |
| SCHEMBL18305060 | 0.70 | CDK4 (0.41) | BRD4CHRM1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107873031-B | Benzoxazinone derivatives and analogs thereof as modulators of TNF activity | UCB生物制药私人有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | UCB BIOPHARMA SPRL (BE) | 2019-05-14 | — | — | US | disclosed |
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | UCB S.A. (BE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134728-A1 | Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity | TNF, NFKBIA, TNFRSF1A | BRD4 1801/4885CHRM1 3318/4885SLC5A2 2150/4885 |
| US-10287299-B2 | Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity | TNF, TNFRSF1A, NFKBIA | BRD4 2210/4885CHRM1 2532/4885SLC5A2 3396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.